Comparison of the neurocognitive outcomes in term infants treated with levetiracetam and phenobarbital monotherapy for neonatal clinical seizures
Küçük Resim Yok
Tarih
2020
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
W B Saunders Co Ltd
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Purpose: This study aims to compare the neurocognitive outcome in term infants who were treated using phenobarbital (PB) and levetiracetam (LEV) monotherapy for neonatal clinical seizures. Methods: Term infants who were treated using PB or LEV monotherapy as the first-line anti-epileptic treatment for neonatal clinical seizures and followed-up in a pediatric neurology outpatient clinic were enrolled in this study. Neurodevelopmental outcome assessments were carried out using the Bayley Scales of Infant Development, third edition (BSID-III), including cognitive, receptive language, expressive language, fine motor and gross motor subscales. Results: the study group consisted of 62 infants who received monotherapy with PB monotherapy (n = 22) and LEV (n = 40). the mean duration of monotherapy treatment was 8 +/- 6 months. There was no statistically significant difference between PB and LEV monotherapy groups concerning each outcome parameter on the BSID-III. There was also no statistically significant difference between PB and LEV monotherapy subgroups excluding the infants with neurodevelopmental impairment with a BSID-III scale score < 7 or a composite score < 85. Conclusion: Our findings suggest that both LEV and PB therapy can be equally safe as monotherapy for neonatal clinical seizures for the neurodevelopmental outcome assessment with BSID-III.
Açıklama
Anahtar Kelimeler
Infant, Monotherapy, Neonatal, Neurodevelopment, Seizure
Kaynak
Seizure-European Journal of Epilepsy
WoS Q Değeri
Q3
Scopus Q Değeri
Q2
Cilt
80
